E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies | Ayya Nadar Janaki Ammal College | Madurai Kamaraj University | India

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus 

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats . He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries .

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd. Earlier, he served as a JRF at TBGRI, Kerala  and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology . His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery . He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth . He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

Title: Chemical profiling and in silico molecular docking studies of phytochemicals from Hydnocarpus macrocarpa Warb: A GC–MS, FTIR, and physico-chemical analysis
Journal: Journal of Molecular Structure
Year: 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Dr. Alexis LeVee at UCLA, United States.

Dr. A. LeVee is a physician-scientist specializing in medical oncology with a focus on breast cancer and translational immunotherapy. Currently a Clinical Instructor at UCLA and a Hematology/Oncology Fellow at City of Hope, Dr. LeVee combines clinical expertise with cutting-edge research in tumor immunology, the microbiome, and novel therapeutic biomarkers. A graduate of Duke University and Tufts Medical School, they are a recipient of multiple national awards, including the ASCO Conquer Cancer Young Investigator Award. With over 10 peer-reviewed publications and leadership in high-impact studies, Dr. LeVee is shaping the future of personalized cancer care and precision immunotherapy.

Publication Profile 

Google Scholar

Education

Dr. LeVee earned a B.A. in Chemistry with minors in Economics and Biology from Duke University (2013) 🧪, followed by an M.D. from Tufts University School of Medicine (2019) 🩺. They completed an Internal Medicine residency at Cedars-Sinai Medical Center (2019–2022) and are currently completing a Hematology/Medical Oncology Fellowship at City of Hope Comprehensive Cancer Center (2022–2025) 🧠. Their diverse training spans top-tier academic institutions and reflects a deep foundation in both clinical medicine and biomedical sciences, equipping them with the tools to integrate research and practice in complex oncology care.

Experience

Dr. LeVee currently serves as Clinical Instructor at UCLA (2025–Present) and Chief Fellow at City of Hope (2023–Present) in the Hematology/Medical Oncology Fellowship Program. Previously, they worked as a Business Analyst at Orange Advisory Group (2013–2015), combining data-driven insight with clinical research. Dr. LeVee has held numerous leadership and committee roles at Cedars-Sinai and City of Hope, contributing to medical education and institutional quality improvement. Their multidisciplinary background and academic leadership experience reflect a strong trajectory toward becoming a leader in translational oncology and academic medicine.

Awards 

Dr. LeVee has earned multiple prestigious awards, including the Young Investigator Award from ASCO, Conquer Cancer Foundation, and MOASC 🏆. Additional accolades include the Coltman Scholar Award and Early Investigator Award from the San Antonio Breast Cancer Symposium (2024), the ASCO Merit Award (2024), and finalist status for the Rubenstein Award for Resident Research (2022). Earlier honors include fellowships from Tufts, American Thoracic Society, and DukeEngage. These awards reflect their innovative research and impact in oncology, particularly in microbiome science, breast cancer immunotherapy, and biomarker discovery.

Research Focus 

Dr. LeVee’s research bridges clinical oncology and translational science, focusing on breast cancer, tumor microenvironment, and immunotherapy 🧬. Their work investigates how microbiota, immune signatures, and biomarkers predict treatment response in triple-negative and HER2+ breast cancers. With funding from ASCO, Biocodex, and City of Hope, Dr. LeVee leads multiple studies analyzing metagenomic and metatranscriptomic profiles of fecal microbiota in patients receiving chemoimmunotherapy. They also explore the cardiotoxic effects of cancer therapies and immuno-radiation synergy. Their goal is to develop precision tools that enhance treatment personalization and patient outcomes in cancer care.

Publication Top Notes

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY

Assoc Prof Dr. Sanli Jin| Oncology Pharmaceuticals |Best Researcher Award

Published on by Top Pharmaceutical

Assoc Prof Dr. Sanli Jin|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Sanli Jin at Peking University School of Nursing,China

PROFILE  

scopus

Early Academic Pursuits 🎓

Sanli Jin embarked on her academic journey at Peking University, one of the most prestigious institutions in China. After joining the School of Nursing in 2004, she pursued her doctoral degree with a specific focus on oncology and nutrition nursing, surgical nursing, and nursing simulation. Her early years of academic training at Peking University provided her with a strong foundation in both theoretical knowledge and practical skills. This combination of educational rigor and practical exposure positioned her to become a leader in the field of nursing education in China.

Professional Endeavors 👩‍🏫

Since completing her doctoral studies, Sanli Jin has been an integral member of the School of Nursing at Peking University, where she serves as an Associate Professor. Her professional work spans various aspects of nursing education, including her involvement in the development and promotion of artificial intelligence-assisted learning methods. Sanli’s teaching excellence has been acknowledged through her role in managing and leading virtual and in-person simulation projects. These projects aim to improve the critical thinking and practical skills of undergraduate nursing students, setting a new standard for nursing education across China.

Sanli has also been actively involved in several key research initiatives, including the development of multimodal teaching methods for diseases of the urinary system and an in-depth study of nutrition-related symptoms in cancer patients undergoing radiotherapy. Through these contributions, she has gained recognition as a leading voice in nursing research and innovation, not only in China but also internationally.

Research and Contributions 📚

Sanli Jin’s research focuses primarily on three main areas: oncology and nutrition nursing, surgical nursing, and nursing simulation. Her contributions in these areas have significantly influenced both clinical practice and education. A key component of her research involves exploring the relationship between nutritional status and patient outcomes in oncology, particularly for patients with head and neck cancers. Her work in this domain has provided valuable insights into managing the complex nutritional needs of cancer patients, and she has earned awards for her research contributions, such as the Second Prize of the Beijing Nursing Society Science and Technology Award.

Another notable aspect of her work is in nursing simulation. Sanli has designed numerous simulation scenarios aimed at enhancing student learning, with her work receiving accolades such as the First Prize in the Case Group of the “Ninth Peking University Innovative Teaching and Learning Application Competition.” These contributions highlight her commitment to improving the quality of nursing education and equipping future nurses with the tools they need to succeed in complex clinical environments.

Accolades and Recognition 🏆

Over her career, Sanli Jin has been the recipient of multiple awards recognizing both her teaching excellence and her contributions to nursing research. Among her most notable accolades are:

  • National First Class Undergraduate Online Course: An award that highlights her contributions to the development of innovative, high-quality online nursing education.
  • Second Prize of the Beijing Nursing Society Science and Technology Award (Technical Achievement Award): Recognizing her work in the nutritional management of cancer patients.
  • Teaching Excellence Award from Peking University Health Science Center: A testament to her commitment to nursing education and student development.

In addition to these awards, Sanli has published nearly 100 papers in prominent national and international journals, further cementing her reputation as a researcher. Her work has garnered 389 citations and earned her an h-index of 11, showcasing the impact and influence of her research within the academic community.

Impact and Influence 🌍

Sanli Jin’s influence extends beyond her individual achievements in research and education. Her work in oncology nursing has had a profound impact on improving patient care, particularly for cancer patients undergoing radiotherapy. Through her research on nutrition and cancer, she has contributed to a better understanding of how dietary interventions can improve patient outcomes. Her efforts have also advanced simulation-based learning in nursing, bridging the gap between theoretical knowledge and practical skills for future generations of nurses.

Her leadership extends to various professional organizations as well. As a member of the MDT Professional Committee for Head and Neck Tumors and the Youth Committee for Cancer Rehabilitation and Nursing, Sanli actively collaborates with other professionals to push the boundaries of nursing science. These memberships allow her to continue influencing the field of oncology nursing, contributing to new standards and best practices.

Legacy and Future Contributions 🌱

Sanli Jin’s contributions have set a strong foundation for the future of nursing in China, particularly in the fields of oncology, nutrition, and nursing simulation. As a pioneer in incorporating artificial intelligence into nursing education, she has paved the way for future generations to embrace technology as a tool for enhancing both learning and patient care. Her ongoing research projects, such as the exploration of virtual simulation’s impact on nursing education, position her at the forefront of innovative teaching methods.

Her legacy is not just one of research and education but also of mentorship and leadership. Sanli has played a key role in nurturing the next generation of nurses and healthcare professionals, instilling in them the values of critical thinking, innovation, and compassion. Her commitment to advancing the field of nursing through both educational initiatives and patient care improvements ensures that her influence will continue to resonate for years to come.

Conclusion 📝

Sanli Jin’s academic and professional journey reflects a deep commitment to improving both nursing education and patient care. From her early academic pursuits to her innovative contributions in research and teaching, she has become a recognized leader in the field of nursing. Her work has not only earned her multiple prestigious awards but has also left a lasting impact on both her students and the broader nursing community. As she continues to explore new avenues of research and education, her legacy as a visionary in nursing will continue to grow, shaping the future of healthcare in China and beyond.

🎓Publication 

Evaluation of the combination of virtual simulation and in-person simulation among undergraduate nursing students: A mixed methods study

  • Authors   : Han, F., Jin, S.
  • Journal    :Nurse Education in Practice
  • Year         :2024

Body composition and dietary intake in patients with head and neck cancer during radiotherapy: A longitudinal study

  • Authors   :Zhuang, B., Zhang, L., Wang, Y., … Jin, S., Lu, Q.
  • Journal    :BMJ Supportive and Palliative Care,
  • Year         :2023

Predictive effect of pretreatment nutritional risk and GLIM-defined malnutrition on the nutrition impact symptom clusters in patients with head and neck cancer undergoing radiotherapy

  • Authors   : Wang, Y., Zhang, L., Zhang, T., … Sun, Y., Lu, Q.
  • Journal    :Head and Neck
  • Year         :2023

Routine replacement versus replacement as clinical indicated of peripheral intravenous catheters: A multisite randomised controlled trial

  • Authors   : Li, J., Ding, Y., Lu, Q., … Lyu, Y., Lin, F.
  • Journal    :Journal of Clinical Nursing,
  • Year         :2023.

Association between body composition and survival in head and neck cancer patients undergoing radiotherapy

  • Authors   : Zhuang, B., Xiao, S., Zhang, L., … Sun, Y., Lu, Q.
  • Journal    :Head and Neck,
  • Year         :2022